Denise P. Carter

CIK: 0001958621

Transaction Breakdown

Open Market Buys (P)6 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

QNRX

Quoin Pharmaceuticals, Ltd.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

QNRX
Quoin Pharmaceuticals, Ltd.
Aug 31, 2026
Purchase(P)
Direct
20.5K shares at avg. $4.88$100K
QNRX
Quoin Pharmaceuticals, Ltd.
Feb 4, 2026
Award(A)
Share Option (Right to Buy)
Direct
318.8K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
May 29, 2025
Award(A)
Share Option (Right to Buy)
Direct
42.9K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
May 29, 2025
Award(A)
Share Option (Right to Buy)
Direct
42K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
Dec 23, 2024
Purchase(P)
Direct
555.6K shares at avg. $0.45$250K
QNRX
Quoin Pharmaceuticals, Ltd.
Dec 9, 2024
Award(A)
Share Option (Right to Buy)
Direct
536.6K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
Sep 4, 2024
Purchase(P)
Direct
23K shares at avg. $0.80$18K
QNRX
Quoin Pharmaceuticals, Ltd.
Sep 4, 2024
Purchase(P)
Direct
8.8K shares at avg. $0.75$7K
QNRX
Quoin Pharmaceuticals, Ltd.
Sep 3, 2024
Purchase(P)
Direct
4.1K shares at avg. $0.66$3K
QNRX
Quoin Pharmaceuticals, Ltd.
Sep 3, 2024
Purchase(P)
Direct
1.8K shares at avg. $0.63$1K

		Type	Shares	Price		Ownership
Aug 31, 2026	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	20,490	$4.88	$99,991	Direct
Feb 4, 2026	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	318,750	-	-	Direct
May 29, 2025	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	42,857	-	-	Direct
May 29, 2025	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	42,039	-	-	Direct
Dec 23, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	555,556	$0.45	$250,000	Direct
Dec 9, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	536,609	-	-	Direct
Sep 4, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	22,988	$0.80	$18,310	Direct
Sep 4, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	8,825	$0.75	$6,602	Direct
Sep 3, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	4,100	$0.66	$2,686	Direct
Sep 3, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	1,822	$0.63	$1,139	Direct

1-10 of 10 transactions

About Carter Denise P.

Carter Denise P. (SEC CIK 0001958621) files insider reports with the SEC as Chief Operating Officer of Quoin Pharmaceuticals, Ltd. (QNRX).

Signal8 holds 7 ownership filings by Carter Denise P., all Form 4s, filed between Sep 5, 2024 and Sep 1, 2026. Those filings report 10 transactions, from Sep 3, 2024 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Carter Denise P.'s filings is in ASHBURN, VA.

Recent filings by Carter Denise P.

Aug 31, 2026: Open-market purchase of QNRX shares (Form 4, code P).
Feb 4, 2026: Grant or award of QNRX derivative securities (Form 4, code A).
May 29, 2025: Grants or awards of QNRX derivative securities (2 lines, Form 4, code A).
Dec 23, 2024: Open-market purchase of QNRX shares (Form 4, code P).
Dec 9, 2024: Grant or award of QNRX derivative securities (Form 4, code A).

Other insiders filing for Quoin Pharmaceuticals, Ltd. (QNRX)

LANGER DENNIS, Director
Myers Michael, Chief Executive Officer
Lawlor Sally Bridget, Chief Financial Officer
Culverwell Anthony James, Director
Cooper Joseph Patrick, Director
SEMBER MICHAEL T, Director

How to read Form 4 transaction codes